» Articles » PMID: 28623858

Roles of ST2, IL-33 and BNP in Predicting Major Adverse Cardiovascular Events in Acute Myocardial Infarction After Percutaneous Coronary Intervention

Overview
Journal J Cell Mol Med
Date 2017 Jun 18
PMID 28623858
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

This study investigated roles of serum ST2, IL-33 and BNP in predicting major adverse cardiovascular events (MACEs) in acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Blood samples were collected from the included AMI patients (n = 180) who underwent PCI. All patients were divided into the MACEs and MACEs-free groups. Enzyme-linked immunosorbent assay was performed to measure serum levels of ST2, IL-33 and BNP. Severity of coronary artery lesion was evaluated by Gensini score. Pearson correlation analysis was used. A receiver operating characteristics curve was drawn to evaluate the potential roles of ST2, IL-33 and BNP in predicting MACEs, and Kaplan-Meier curve to analyse the 1-year overall survival rate. Logistic regression analysis was conducted to analyse the independent risk factors for MACEs. Compared with the MACEs-free group, the serum levels of ST2, IL-33 and BNP were significantly higher in the MACEs group. Serum levels of ST2, IL-33 and BNP were positively correlated with each other and positively correlated with Gensini score. The area under curves of ST2, IL-33 and BNP, respectively, were 0.872, 0.675 and 0.902. The relative sensitivity and specificity were, respectively, 76.27% and 85.92%, 69.49% and 58.68%, as well as, 96.61% and 77.69%. Serum levels of ST2, IL-33 and BNP were independent risk factors for MACEs. The 1-year overall survival rate was higher in AMI patients with lower serum levels of ST2, IL-33 and BNP. In conclusion, serum levels of ST2, IL-33 and BNP have potential value in predicting MACEs in AMI patients undergoing PCI.

Citing Articles

Short-term predictive value of sST2 in patients with STEMI following primary PCI: a prospective observational study.

Huang S, Yu L, Sun G, Zhang Z BMC Cardiovasc Disord. 2025; 25(1):21.

PMID: 39819309 PMC: 11737151. DOI: 10.1186/s12872-025-04488-z.


Soluble suppression of tumorigenicity 2 associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction.

Du X, Liu J, Zhou J, Ren Y, Gul N, Chen L BMC Cardiovasc Disord. 2024; 24(1):691.

PMID: 39614185 PMC: 11607795. DOI: 10.1186/s12872-024-04364-2.


Examining the Long-Term Prognostic Significance of Serum sST2: Influence of Myocardial Infarction History and Subgroup Level Standardization.

Guan X, Guan L, Cheng G, Sun Z, Wang C J Inflamm Res. 2024; 17:7733-7744.

PMID: 39479262 PMC: 11522014. DOI: 10.2147/JIR.S482475.


The Role of Alarmins in the Pathogenesis of Atherosclerosis and Myocardial Infarction.

Kielbowski K, Skorka P, Plewa P, Bakinowska E, Pawlik A Curr Issues Mol Biol. 2024; 46(8):8995-9015.

PMID: 39194749 PMC: 11352985. DOI: 10.3390/cimb46080532.


Predictive Value of the Modified GRACE Scoring System for All-Cause Mortality in Patients with Acute Myocardial Infarction.

Yan J, Deng C, Wang S, Aimaitijiang M, Wu T, Zheng Y Rev Cardiovasc Med. 2024; 24(6):161.

PMID: 39077519 PMC: 11264122. DOI: 10.31083/j.rcm2406161.


References
1.
Sims J . IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol. 2002; 14(1):117-22. DOI: 10.1016/s0952-7915(01)00306-5. View

2.
Zhang K, Zhang X, Mi Y, Liu J . Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction. Chin Med J (Engl). 2013; 126(19):3628-31. View

3.
Weir R, Miller A, Murphy G, Clements S, Steedman T, Connell J . Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010; 55(3):243-50. DOI: 10.1016/j.jacc.2009.08.047. View

4.
Wang Y, Fu R, Wang Z, Bao H, Chen Y, Yang F . Assessing the Quality of Care for Patients With Acute Myocardial Infarction in China. Clin Cardiol. 2015; 38(6):327-32. PMC: 6711066. DOI: 10.1002/clc.22405. View

5.
Sato H, Kinjo K, Ito H, Hirayama A, Nanto S, Fukunami M . Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID Study. Circ J. 2007; 72(1):17-22. DOI: 10.1253/circj.72.17. View